0 281

Cited 0 times in

Effect of statin on hepatocellular carcinoma in patients with type 2 diabetes: A nationwide nested case-control study

 Gyuri Kim  ;  Suk-Yong Jang  ;  Eugene Han  ;  Yong-ho Lee  ;  Se-young Park  ;  Chung Mo Nam  ;  Eun Seok Kang 
 INTERNATIONAL JOURNAL OF CANCER, Vol.140(4) : 798-806, 2017 
Journal Title
Issue Date
Adult ; Aged ; Aged, 80 and over ; Carcinoma, Hepatocellular/epidemiology* ; Case-Control Studies ; Comorbidity ; Diabetes Mellitus, Type 2/drug therapy ; Diabetes Mellitus, Type 2/epidemiology* ; Dyslipidemias/drug therapy ; Dyslipidemias/epidemiology ; Fatty Liver/epidemiology ; Female ; Follow-Up Studies ; Hepatitis, Viral, Human/epidemiology ; Humans ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/pharmacology* ; Hydroxymethylglutaryl-CoA Reductase Inhibitors/therapeutic use ; Hypoglycemic Agents/therapeutic use ; Incidence ; Liver Neoplasms/epidemiology* ; Logistic Models ; Male ; Middle Aged ; Odds Ratio ; Republic of Korea/epidemiology ; Risk ; Socioeconomic Factors
cohort study ; diabetes ; hepatocellular carcinoma ; liver disease ; statin
Relationship on new statin use and the risk of hepatocellular carcinoma (HCC) in patients with incident type 2 diabetes mellitus (T2DM), who might be at the risk of developing HCC, is uncertained. A nationwide population-based nested case-control study was conducted within the National Health Insurance Service National Sample Cohort 2002-2013 in Korea. Newly prescribed statin after newly diagnosed T2DM was defined as statin use. Controls were matched to case patients on age, sex, follow-up time, and the date of diabetes diagnosis at a five-to-one ratio. Odds ratios (ORs) for associations of statin use with HCC were calculated using conditional logistic regression. After at least a 5-year HCC-free period, there were 229 incident HCC cases and 1,145 matched controls from 47,738 patients with incident diabetes. Of these 229 incident HCC cases, 27 (11.8%) were statin users, whereas 378 (33.0%) were statin users among 1,145 controls. Statin use was associated with a reduced risk of HCC development (adjusted OR [AOR]= 0.36, 95% confidence interval [CI] 0.22-0.60) after adjustment for chronic viral hepatitis, liver cirrhosis, alcoholic liver disease, previous cancer, aspirin use, insulin use, sulfonylurea use, metformin use, thiazolidinedione use, history of chronic obstructive pulmonary disease, Charlson comorbidity score, household income level, and residential area. Risk reduction was accentuated with an increase of cumulative defined daily doses (cDDD) compared with non-users (AORs 0.53, 0.36, 0.32, and 0.26 in ≤60, 60-180, 181-365, and >365cDDD, respectively; P for trend <0.0001). The risk reduction was apparent in the presence of liver disease (AOR = 0.27, 95% CI 0.14-0.50), including heterogeneous groups of clinical diagnosis of liver disease, but not significant in the absence of liver disease (AOR = 0.64, 95% CI 0.32-1.29). Among patients with new onset T2DM, statin use before HCC diagnosis may have a beneficial inhibitory effect on HCC development in a dose-dependent manner, especially in individuals with liver disease.
Full Text
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Internal Medicine (내과학교실) > 1. Journal Papers
1. College of Medicine (의과대학) > Dept. of Preventive Medicine and Public Health (예방의학교실) > 1. Journal Papers
Yonsei Authors
Kang, Eun Seok(강은석) ORCID logo https://orcid.org/0000-0002-0364-4675
Kim, Gyuri(김규리)
Nam, Chung Mo(남정모) ORCID logo https://orcid.org/0000-0003-0985-0928
Lee, Yong Ho(이용호) ORCID logo https://orcid.org/0000-0002-6219-4942
Han, Eu Gene(한유진)
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.